Known targets — ChEMBL curated mechanism
ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 15/20 | 0.84 |
| ▸ | DPP7 | Q9UHL4 | 10/20 | 0.84 |
| ▸ | DPP8 | Q6V1X1 | 8/20 | 0.84 |
| ▸ | DPP9 | Q86TI2 | 7/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL21638348 | 1.00 | DPP4 (0.84) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL353709 | 0.92 | DPP4 (1.00) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL12291433 | 0.92 | DPP4 (1.00) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL846295 | 0.92 | DPP4 (1.00) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL392505 | 0.92 | DPP4 (1.00) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL356202 | 0.92 | DPP4 (1.00) | DPP4DPP7DPP8DPP9 | |
| Hydrochloric Acid SCHEMBL5708932 | 0.90 | DPP4 (0.97) | DPP4DPP7DPP8DPP9 | |
| Hydrochloric Acid SCHEMBL5708931 | 0.90 | DPP4 (0.97) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL28071366 | 0.82 | DPP4 (0.82) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL28071368 | 0.82 | DPP4 (0.82) | DPP4DPP7DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4554574-A2 | SMALL MOLECULE REGULATORS OF ALVEOLAR TYPE 2 CELL PROLIFERATION FOR THE TREATMENT OF PULMONARY DISEASES | The Scripps Research Institute (US) | 2025-05-21 | — | — | EP | claimed |
| CN-119698278-A | Small molecule modulators of alveolar type 2 cell proliferation for the treatment of pulmonary diseases | 斯克里普斯研究学院 | 2025-03-25 | — | — | CN | claimed |
| US-20240115577-A1 | SMALL MOLECULE REGULATORS OF ALVEOLAR TYPE 2 CELL PROLIFERATION FOR THE TREATMENT OF PULMONARY DISEASES | THE SCRIPPS RESEARCH INSTITUTE | 2024-04-11 | — | — | US | claimed |
| WO-2024015889-A2 | SMALL MOLECULE REGULATORS OF ALVEOLAR TYPE 2 CELL PROLIFERATION FOR THE TREATMENT OF PULMONARY DISEASES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2024-01-18 | — | — | WO | claimed |
| US-12595288-B2 | Vasopressin-2 receptor antagonist peptides and uses thereof | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2026-04-07 | — | — | US | disclosed |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260001873-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2026-01-01 | — | — | US | disclosed |
| US-12465564-B2 | Oral and nasal compositions and methods of treatment | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250339367-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250277062-A1 | BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF | THE BROAD INSTITUTE, INC. | 2025-09-04 | — | — | US | disclosed |
| US-12404348-B2 | Bifunctional chimeric molecules for labeling of kinases with target binding moieties and methods of use thereof | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-12403090-B2 | Oral film compositions and dosage forms having precise active dissolution profiles | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-20220105057-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2022-04-07 | — | — | US | disclosed |
| US-20220105064-A1 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER | BIOGEN SWISS MFG GMBH (CH) | 2022-04-07 | — | — | US | disclosed |
| US-11285180-B2 | Methods of enhancing the potency of incretin-based drugs in subjects in need thereof | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2022-03-29 | — | — | US | disclosed |
| US-11279690-B2 | Inhibitors of glutaminyl cyclase | VIVORIAN THERAPEUTICS N.V | 2022-03-22 | — | — | US | disclosed |
| US-20220079897-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2022-03-17 | — | — | US | disclosed |
| CN-108218849-B | Novel inhibitors | 维沃永治疗公众有限公司 | 2022-03-01 | — | — | CN | disclosed |
| US-11248031-B2 | Methods of treating diseases associated with fibrosis using modified FGF-21 polypeptides | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-02-15 | — | — | US | disclosed |
| US-11229645-B2 | Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy | INSTITUT PASTEUR (FR) | 2022-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001873-A1 | NOVEL INHIBITORS | GLS, GLS2, SULT1E1 | DPP4 798/4885DPP7 573/4885DPP8 521/4885 |
| US-12595288-B2 | Vasopressin-2 receptor antagonist peptides and uses thereof | AVPR2, AVPR1A, AVPR1B | DPP4 1313/4885DPP7 1960/4885DPP8 2104/4885 |
| US-11248031-B2 | Methods of treating diseases associated with fibrosis using modified FGF-21 polypeptides | FGF1, HDGF, FGF2 | DPP4 2632/4885DPP7 1930/4885DPP8 1978/4885 |
| US-20250277062-A1 | BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF | ERBB2, ACP1, TK1 | DPP4 4587/4885DPP7 3780/4885DPP8 4018/4885 |
| US-12404348-B2 | Bifunctional chimeric molecules for labeling of kinases with target binding moieties and methods of use thereof | ERBB2, ACP1, TK1 | DPP4 4587/4885DPP7 3780/4885DPP8 4018/4885 |
| US-20220079897-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | DPP4 108/4885DPP7 431/4885DPP8 1120/4885 |
| US-20220105057-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | DPP4 70/4885DPP7 474/4885DPP8 1101/4885 |
| US-20240115577-A1 | SMALL MOLECULE REGULATORS OF ALVEOLAR TYPE 2 CELL PROLIFERATION FOR THE TREATMENT OF PULMONARY DISEASES | DPP4, DPP7, ING2 | DPP4 1/4885DPP7 2/4885DPP8 8/4885 |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | SORD, SLC6A13, CACNA1A | DPP4 705/4885DPP7 878/4885DPP8 1717/4885 |
| US-11279690-B2 | Inhibitors of glutaminyl cyclase | QPCT, QPCTL, GLUL | DPP4 1109/4885DPP7 861/4885DPP8 1698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.